Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
This study is currently recruiting participants.
Study NCT00274742   Information provided by Micromet AG
First Received: January 10, 2006   Last Updated: August 11, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Non-Hodgkin's Lymphoma, Relapsed
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Non-Hodgkin
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Blinatumomab (MT103)
Sponsors listed in this trial
Micromet AG


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services